ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial

Ren, Shengxiang; Wang, Xicheng; Han, Bao-Hui; Pan, Yueyin; Zhao, Jun; Cheng, Yufeng; Hu, Sheng; Liu, Tianshu; Li, Yalun; Cheng, Ying; Feng, Jifeng; Yi, Shanyong; Gu, Shanzhi; Gao, Shegan; Luo, Yongzhong; Liu, Ying; Liu, Caigang; Duan, Huijie; Wang, Shuni; Yang, Xinfeng; Fan, Jia*; Zhou, Caicun*复旦大学; 广东药学院; 山东大学; 四川大学; 郑州大学; 中国医科大学; 1
Journal for ImmunoTherapy of Cancer2024-2DOI: 10.1136/jitc-2023-007227
3阅读
引用收藏
分享

摘要

Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase inhibitor) as a first-line treatment for advanced or metastatic NSCLC patients with a programmed death ligand-1 (PD-L1) tumor proportion score (TPS) of >= 1%, in an open-label, multicenter, phase 2 basket trial.Methods Eligible patients received camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus oral famitinib at an initial dose of 20 mg once daily. The primary endpoint was the objective response rate (ORR), as assessed by the investigator per Response Evaluation Criteria in Solid Tumors V.1.1. Key secondary endpoints included disease control rate (DCR), duration of respons, progression-free survival (PFS), overall survival (OS), 12-month OS rate, and safety profile.Results Of the enrolled 41 patients, 21 (51.2%) had a PD-L1 TPS of 1-49%. As of the cut-off date on June 22, 2022, the combination regimen of camrelizumab and famitinib achieved an ORR of 53.7% (95% CI 37.4% to 69.3%) and a DCR of 92.7% (95% CI 80.1% to 98.5%). The median PFS was 16.6 months (95% CI 8.3 to not reached), and OS data were not yet mature, with an estimated 12-month OS rate of 76.8% (95% CI 60.0% to 87.3%). The most common treatment-related adverse events of grade 3 or higher included hypertension (22.0%), increased alanine aminotransferase (12.2%), decreased neutrophil count (9.8%), proteinuria (7.3%), decrease platelet count (7.3%), and hypokalemia (7.3%). One (2.4%) patient died from grade 5 hemoptysis, which was considered possibly related to the study treatment by the investigator.Conclusion Camrelizumab plus famitinib demonstrated promising antitumor activity in advanced or metastatic NSCLC patients and had an acceptable safety profile. These findings suggest that this combination regimen could be an alternative therapeutic option and warrant further investigation.Trial registration number NCT04346381.

学科与关键词

关键词
Drug TherapyCombination
相关
加载中…
  • Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial
    Ren, S.; Wang, X.; Han, B.; Pan, Y.; Zhao, J.; Cheng, Y.; Hu, S.; Liu, T.; Li, Y.; Cheng, Y.; Feng, J.; Yi, S.; Gu, S.; Gao, S.; Luo, Y.; Liu, Y.; Liu, C.; Duan, H.; Zhou, C.; Fan, J.
  • Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open- label, multicenter phase 2 basket study
    Xia, Lingfang; Peng, Jin; Lou, Ge; Pan, Mei; Zhou, Qi; Hu, Wenjing; Shi, Huirong; Wang, Li; Gao, Yunong; Zhu, Jianqing; Zhang, Yu; Sun, Rong; Zhou, Xianfeng; Wang, Quanren; Wu, Xiaohua*Journal for ImmunoTherapy of Cancer, 2022, 10(1): e003831.被引 18
  • Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study
    Pu, Xingxiang; Wang, QianZhi; Liu, Liyu; Chen, Bolin; Li, Kang; Zhou, Yu; Sheng, Zengmei; Liu, Ping; Tang, Yucheng; Xu, Li; Li, Jia; Kong, Yi; Xu, Fang; Xu, Yan; Wu, Lin*Cancer Medicine, 2023, 12(7): 7724-7733.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal for ImmunoTherapy of Cancer
发表日期
2024-02
卷期
第 12 卷, 第 2 期
页码
e007227
DOI
10.1136/jitc-2023-007227
成果收录
SCIE
资助标注
Science and Technology Commission of Shanghai Municipality [21XD1423200]; National Key Clinical Program on thoracic oncology(2023)

作者

  • R

    Ren, Shengxiang (第一作者)

    shanghai pulm hosp

  • W

    Wang, Xicheng

    1 · guangdong pharmaceut univ

查看全部 22 位作者收起作者
  • H

    Han, Bao-Hui

  • P

    Pan, Yueyin

    1 · anhui prov hosp · ustc

  • Z

    Zhao, Jun

  • C

    Cheng, Yufeng

    shandong univ

  • H

    Hu, Sheng

    hubei canc hosp

  • L

    Liu, Tianshu

    fudan univ

  • L

    Li, Yalun

    sichuan univ

  • C

    Cheng, Ying

  • F

    Feng, Jifeng

    jiangsu inst canc res · nanjing med univ

  • Y

    Yi, Shanyong

  • G

    Gu, Shanzhi

    hunan canc hosp

  • G

    Gao, Shegan

    1 · henan univ

  • L

    Luo, Yongzhong

    hunan canc hosp

  • L

    Liu, Ying

    zhengzhou univ

  • L

    Liu, Caigang

    china med univ

  • D

    Duan, Huijie

  • W

    Wang, Shuni

  • Y

    Yang, Xinfeng

  • F

    Fan, Jia (通讯)

    fudan univ

  • Z

    Zhou, Caicun (通讯)

    shanghai pulm hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417